Incozen focuses on discovering and developing promising small molecular compounds as potential therapeutic options. Incozen aims to accrue value through creation of sustainable pipeline of NCEs leveraging rich scientific experience of its well experienced R&D team. Incozen initiated discovery programs in the areas of Oncology and Allergy/Inflammation in collaboration with Rhizen Pharma SA, Switzerland. Incozen’s team was successful in creating respectable IP in the selected areas in the last two year and is in the process of developing these inventions through clinical stages in the coming future.

R&D Approach:

• Integrated drug discovery and development advancing newly designed molecules in an iterative data driven environment.
• Team of richly qualified scientists with global academic and industrial experience, who have the proven record of delivering clinical candidates.
• Research efforts based on validated targets in chronic therapeutic areas with large marketing potential.

• Research strategy to collaborate with global partners at appropriate stages, leveraging the pipeline value, that helps in faster progression of selected programs.
• Focus on innovation to create differentiating products that will add significant value to the late stage pipelines of partnering companies.